Targeted Strategies for Today's Evolving Markets

MissionIR Blog

VolitionRx Ltd. (VNRX) Cancer Diagnostic Tool Yield Hope amid Global Epidemic of Prostate Cancer

Life sciences company VolitionRx is engaged in the development of blood-based diagnostic tests for different types of cancer. Demonstrating significant headway with its NuQ® assays, VolitionRx recently released data from a pilot study of the test to diagnose prostate cancer.

Results from the trial show that NuQ assays were able to detect roughly 80 percent of prostate cancer cases and also has the ability to differentiate between colorectal and prostate cancer.

As VolitionRx continues to develop its NuQ tests, it’s impossible to ignore the global need for such technology and the value of the company’s ongoing research and development initiatives.

More than 1.1 million cases of prostate cancer were recorded in 2012, accounting for approximately 8 percent of all new cancer cases and 15 percent of cancer in men, according to the latest figures from the World Cancer Research Fund International.

Furthermore, prostate cancer is the most frequently diagnoses non-skin cancer in the United States, and the third leading cause of cancer deaths in the nation, reports the National Institutes of Health (NIH). An NIH online report entitled “The Worldwide Epidemiology of Prostate Cancer: Perspectives from Autopsy Studies,” concludes in recognition of the value of accurate diagnostics.

“The clinical incidence, mortality, and to a lesser degree prevalence of prostate cancer varies among various geographical regions of the world. The approach to screening, early detection initiatives, and availability of treatment modalities has a major impact on disease epidemiology.”

By detecting two major cancers with a blood test, VolitionRx has not only achieved an important company milestone, but has also warranted further investigation for panels of its NuQ tests as a cancer diagnostic tool.

For more information, visit

Let us hear your thoughts below:

This entry was posted in VolitionRx Ltd. VNRX. Bookmark the permalink.

Comments are closed.